Categories AlphaGraphs, Earnings, Health Care

Merck (MRK) sales decline 8% in Q2 2020; raises FY20 outlook

Merck (NYSE: MRK) reported an 8% drop in second quarter sales, reflecting the negative impact of COVID-19. However, sales of $10.9 billion and adjusted EPS of $1.37 topped Street’s views. The pharma giant lifted its outlook for fiscal 2020.

MRK stock rose about 3% in the pre-market trading session following its earnings announcement.

Merck (MRK) Q2 2020 Earnngs Infograph

Merck narrowed and lifted FY20 revenue guidance to a range of $47.2 billion to $48.7 billion.

The Kenilworth, New Jersey-based firm also narrowed and raised its earnings outlook for FY20. GAAP EPS is now expected to be between $4.58 and $4.73 and non-GAAP EPS is now expected to be between $5.63 and $5.78.

Merck is accelerating two COVID-19 vaccine development efforts and a novel antiviral candidate. “We are conscious of our abiding responsibility to help advance vaccine and antiviral efforts as part of the global response to SARS-CoV-2 and to ensure broad, equitable and affordable global access to any medicines and vaccines we bring forward,” said CEO Kenneth Frazier.

Looking forward to listening to management/analysts comments on quarterly results? Stay tuned here for Merck Q2 2020 earnings call transcript

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top